+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID05981703

Study of HPK1 Inhibitor BGB-26808 Alone or with Tislelizumab and Chemotherapy in Adults with Advanced Solid Tumors

Led by BeOne Medicines · Updated on 2026-09-28

337

Participants Needed

28

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating BGB-26808, a HPK1 inhibitor, alone or combined with tislelizumab, an anti-PD-1 antibody, in adults with advanced solid tumors. This phase 1 trial aims to find the recommended dose for BGB-26808 and to assess its safety, tolerability, and preliminary antitumor effects. The study is open-label, nonrandomized in dose escalation, and later includes dose expansion phases.

CONDITIONS

Brief Title

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Research Team

S

Study Director

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here